AGP Executive Report
Last update: an hour agoEndocrine Care Watch: New ENDO 2026 research finds testosterone prescribing often misses guideline-based diagnostic testing and may be given despite contraindications, raising safety concerns for men treated for “low T” symptoms. Medication Use Reality Check: Another ENDO 2026 study shows many people on GLP-1s for type 2 diabetes stop within a year, but a majority restart later—highlighting adherence challenges. Menopause Relief: A real-world ENDO 2026 study reports the non-hormone drug fezolinetant improved hot flashes plus anxiety and depression symptoms within weeks. Early-Life Exposure Concerns: ENDO 2026 presentations report endocrine-disrupting chemicals in breast milk and infant urine up to 6 months, and separate work links early DEHP exposure to lasting anxiety-like behavior in male rats. Food Safety: FDA issued a Class I recall for Alfredo sauce sold in 41 states due to possible Salmonella contamination. Local Health Education: University of Illinois Extension launches a free monthly “Lunch N Learn” series in Ottawa focused on healthy eating and hands-on cooking. Policy & Rights: Illinois’ “right to die” law faces a new federal lawsuit from patients and disability organizations ahead of its Sept. 12 start date.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
